id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-005481-00rezmqj	Reid, T	Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial	2001-11-22		.txt	text/plain	6637	355	44	[21] [22] [23] Tumor-selective viral replication and necrosis were demonstrated, and the treatment was well-tolerated without dose-limiting toxicities; flu-like symptoms and injection site pain were frequently noted. [24] [25] [26] [27] While all recurrent head and neck cancer patients on the combination viral and chemo-therapy clinical trial received intravenous chemotherapy (cisplatin and 5-fluorouracil), the response rate of tumors injected with ONYX-015 was significantly higher than in tumors that were not injected. Therefore, based on the favorable clinical toxicity and efficacy profile with intratumoral injection, and preclinical efficacy following intravascular administration, we performed a phase I/II dose escalation trial of ONYX-015 administered via the hepatic artery to patients with metastatic gastrointestinal carcinomas (primarily colorectal) to the liver. We performed a phase I dose-escalation trial of the replication-selective adenovirus ONYX-015 administered by hepatic arterial infusion, alone and in combination with intravenous 5-FU and LV, in patients with liver metastases from gastrointestinal carcinomas.	./cache/cord-005481-00rezmqj.txt	./txt/cord-005481-00rezmqj.txt